Fractyl Health Reports Q4 and FY25 Financial Results and Business Updates

Fractyl Health completed randomization in the REMAIN-1 Pivotal Cohort and expects topline 6-Month data in early Q4 2026. The FDA provided favorable feedback on the De Novo classification request, with submission expected in late Q4 2026. New post-hoc analyses from the REMAIN-1 Midpoint Cohort showed a statistically significant ablation length-dependent treatment effect on post-GLP-1 weight maintenance at 6 months. Fractyl reiterates its cash runway guidance into early 2027, beyond anticipated Pivotal data readout.